Preclinical testing of the Akt inhibitor
β
Camilla Evangelisti; Francesca Ricci; Pierluigi Tazzari; Francesca Chiarini; Mic
π
Article
π
2010
π
John Wiley and Sons
π
English
β 659 KB
## Abstract Over the past 20 years, survival rates of Tβcell acute lymphoblastic leukemia (TβALL) patients have improved, mainly because of advances in polychemotherapy protocols. Despite these improvements, we still need novel and less toxic treatment strategies targeting aberrantly activated sign